ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
Complejo Asistencial Universitario de Burgos
Burgos, EspañaPublications en collaboration avec des chercheurs de Complejo Asistencial Universitario de Burgos (9)
2024
2023
-
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications, Vol. 14, Núm. 1
2022
-
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
Cancers, Vol. 14, Núm. 24
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
2021
-
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Pancreatology, Vol. 21, Núm. 1, pp. 215-223
2019
-
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580
2018
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
2015
-
Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors
Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 381-400
2012
-
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
Clinical and Translational Oncology, Vol. 14, Núm. 8, pp. 606-612